Lumakras is named as an intervention in 8 current clinical trials in our Mexico, UK, USA, France, Spain, Belgium, Netherlands, Italy, Canada, Japan, Australia, China, Germany, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Brazil, South Korea and Taiwan registers. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Verastem, Inc (3). The most-studied condition is Ovarian Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 2 |
| Non Small Cell Lung Cancer | 1 |
| KRAS Activating Mutation | 1 |
| Metastatic Colorectal Cancer | 1 |
| Lung Adenocarcinoma | 1 |
| Lung Non-Small Cell Carcinoma | 1 |
| Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | 1 |
| Stage IV Lung Cancer AJCC v8 | 1 |
| Advanced Malignant Solid Neoplasm | 1 |
| Metastatic Malignant Solid Neoplasm | 1 |
| Low Grade Ovarian Serous Adenocarcinoma | 1 |
| Endometrioid Cancer | 1 |
| Mucinous Ovarian Cancer | 1 |
| High Grade Serous Ovarian Cancer | 1 |
| Cervical Cancer | 1 |
| Low Grade Serous Ovarian Cancer | 1 |
| Myelodysplastic Syndromes | 1 |
| Chronic Myelomonocytic Leukemia | 1 |
| Acute Myeloid Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Verastem, Inc | 3 |
| Amgen | 1 |
| SWOG Cancer Research Network | 1 |
| National Cancer Institute (NCI) | 1 |
| University of Oklahoma | 1 |
| Clinical Hub for Interventional Research (CHOIR) | 1 |
A trial with sites in more than one country appears in each of those registers.
8 current trials in our Mexico, UK, USA, France, Spain, Belgium, Netherlands, Italy, Canada, Japan, Australia, China, Germany, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Brazil, South Korea and Taiwan registers name Lumakras (also registered as AMG 510) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 8 trials are recruiting: 2 with sites in Mexico, 1 with sites in UK, 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Belgium, 1 with sites in Netherlands, 1 with sites in Italy, 1 with sites in Canada, 1 with sites in Japan, 2 with sites in Australia, 1 with sites in China, 1 with sites in Germany, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Turkey, 1 with sites in Brazil, 1 with sites in South Korea and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Verastem, Inc (3), Amgen (1), SWOG Cancer Research Network (1) and National Cancer Institute (NCI) (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lumakras works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lumakras works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lumakras (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.